FinVector opened a new production plant in Savilahti – City of Kuopio awarded important partners for significant investment

FinVector and Ferring Pharmaceuticals have opened a new gene therapy production facility, Finport, in Kuopio, Finland, on October 3. The facility specialises in the production of gene therapy viral-based drugs for the treatment of bladder cancer. Finport is a clean-room, state-of-the-art production facility that can produce large quantities of the drug efficiently and safely.

The completion of Finport and the operation of FinVector have had a significant economic impact on the Kuopio region in recent years. Cooperation with local authorities and financial partners has been close. FinVector is one of the largest private sector employers in the Kuopio region. The company strengthens Kuopio’s knowledge and research centre in the field of health technology.

“We have come a long way together to reach this point, the opening of Finport. City of Kuopio is privileged to provide a home for this world-class pharmaceutical factory and its international staff,” says Soile Lahti, Mayor of Kuopio.

In recognition of the importance of the event, on 3 October City of Kuopio awarded the Kuopio Medal to Frederic Paulsen (Chairman Emeritus of the Ferring Group) and the City of Kuopio Gold Medal to Jean-Frederic Paulsen (Executive Chairman of Ferring Pharmaceuticals and Ferring Ventures). These are the most important honours awarded by the City of Kuopio in recognition of outstanding service to Kuopio.